Anti-NETs antibodies in #COVID. 1️⃣ correlate➖ w/ SpO2/FiO2 ratio (IgG r=-0.17 IgM r=-0.30 2️⃣correlate➕ w/ ⬆️D-dimer (IgG r=0.33 IgM r=0.19 3️⃣ ⬆️ in pts requiring MV In a study of 328 pts. Probably driving complement activation! #ACR21 #Abst1430 @RheumNow https://t.co/2MCrLueTzN

AQUILA study, SEC improved disease activity, depression of PsA patients in both men and women. Women showed overall higher burden of disease. SEC effective up to 52 weeks with high treatment retention rates irrespective of gender @RheumNow #ACR21 Abst#1334 https://t.co/9cPGq5M648 https://t.co/iTrkRWoot0

• How Does Gender Affect Secukinumab Treatment Outcomes and Retention Rates in Pa…

Low incidence of GI-related serious AE in pooled 1 year data from VOY1&2 and DISC1&2 trials of Guselkumab for PsA/PsO treatment ⭐️no new onset IBD or exacerbation of IBD ⭐️no uveitis, infections, TB Abs#1342 #ACR21 @RheumNow https://t.co/x3OmLgInV0

• Low Incidence of Gastrointestinal-related and Overall Serious Adverse Events Am…

⭐️ Wanna catch up with the latest news on JAKi safety trials presented at #ACR21? Our @Rheumnow interview with @ErnestChoy1 is out. Link below https://t.co/zYb4rXcw1x https://t.co/i39xXnfC3Q

• JAKi Safety: Dr. Ernest Choy with Dr. Aurelie Najm - YouTube

You can <but not as frequently> treat to target in #RheumatoidArthritis with virtual v in person visits. 45 docs in 18 practices comparing in person to virtual. In person wins but not by a large gap! Abst#1448 @dansolomon @RheumNow #ACR21 #ACRBest session today coming up https://t.co/8lcuMW0bwb

SEC demonstrated significantly longer time to flare vs PBO w/ sustained improvement of ERA and JPsA signs and symptoms up to Wk 104. No new safety signals. Plenary Abs 1424 #ACR21 #RheumNow @RheumNow https://t.co/VF2HmJ3Ha9 https://t.co/ApYFusADHX

• Secukinumab Treatment in Children and Adolescents with Enthesitis-related Arthr…

RheumNow’s expanded coverage of the #ACR21 annual meeting is sponsored in part by @Novartis. All content chosen by RheumNow & its Faculty.

#PJP prophylaxis debate at #lupus hub if on #prednisone + immune suppression. #SLE has ⤴️septra side effects. Don’t know right answer. NNT v NNH is unknown. I don’t use it in #SLE. @RheumNow #ACR21 8M212

Post-hoc analysis of Deucravacitinib (TYK2i) for tx of PsA showed similar efficacy in pts with and without background csDMARD use. ⭐️>60% w/ background csDMARD use, majority of which was MTX ⭐️no difference in AE #ACR21 Abs#1352 @RheumNow https://t.co/nIJT7rNkJP https://t.co/bq0x1Ywguo

• Deucravacitinib Efficacy in Psoriatic Arthritis (PsA) by Baseline DMARD Use: Ex…

Wonderful interview @KDAO2011 and @alhkim with great learning points on #BCell #Immunology #ACR21 @RheumNow https://t.co/1292FNZanL

• TheDaoIndex on Twitter: &quot;Watch my Exclusive Interview with #Wowkim: &#10;D…